TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 1nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 1nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 25nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 34nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 40nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 50nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 50nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 70nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 70nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 75nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 80nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 80nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 80nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 90nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 90nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 90nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair